{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:36Z","timestamp":1791924756114,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clgc.2019.07.020","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:28:56Z","timestamp":1565004536000},"page":"e1104-e1107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review"],"prefix":"10.1016","volume":"17","author":[{"given":"Nilgun","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6222-921X","authenticated-orcid":false,"given":"Ferhat","family":"Balgetir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Burak","family":"Er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.07.020_bib1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.07.020_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.07.020_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.clgc.2019.07.020_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced Guillain-Barr\u00e9 Syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clgc.2019.07.020_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.07.020_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","article-title":"A\u00a0case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use","volume":"142","author":"Jacob","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2019.07.020_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu","year":"2017","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.clgc.2019.07.020_bib8","doi-asserted-by":"crossref","first-page":"1093858","DOI":"10.1155\/2017\/1093858","article-title":"A\u00a0case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis","volume":"2017","author":"Sakai","year":"2017","journal-title":"Case Rep Med"},{"key":"10.1016\/j.clgc.2019.07.020_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 Syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.clgc.2019.07.020_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp-2017-316510","article-title":"Acute demyelinating polyneuropathy induced by nivolumab","volume":"89","author":"Fukumoto","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clgc.2019.07.020_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jns.2018.04.028","article-title":"Nivolumab-induced acute demyelinating polyradiculo neuropathy mimicking Guillain-Barr\u00e9 syndrome","volume":"390","author":"Nukui","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.clgc.2019.07.020_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MJT.0000000000000771","article-title":"Nivolumab-associated Guillain-Barre Syndrome in a patient with non-small-cell lung cancer","volume":"25","author":"Thapa","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.clgc.2019.07.020_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030296","article-title":"PD-1 inhibitors-related neurological toxicities in patients with non-small-cell lung cancer: a literature review","volume":"11","author":"Mirabile","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2019.07.020_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.07.020_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.07.020_bib16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clgc.2019.07.020_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clgc.2019.07.020_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.07.020_bib19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.07.020_bib20","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis","volume":"29s","author":"Callahan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.07.020_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anticytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clgc.2019.07.020_bib22","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.07.020_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clgc.2019.07.020_bib24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:53Z","timestamp":1761564653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319302484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1558767319302484"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.07.020","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}